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NM23-HI immunostaining is inversely associated with
tumour staging but not overall survival or disease
recurrence in colorectal carcinomas
PY Cheah, X Cao, KW Eu and F Seow-Choen
Department of Colorectal Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Republic of Singapore
Summary The NM23-H1 gene product has been recently identified as a potential metastasis suppressor. Studies on breast carcinomas have
shown an inverse correlation between NM23-H1 status and stage of carcinogenesis and overall survival. However, in colorectal cancer,
conflicting data have been reported. This study aimed to investigate whether NM23-H1 immunostaining is correlated with tumour stage,
overall survival, disease recurrence, tumour differentiation, age and sex in colorectal carcinomas for the Singapore population using chi-
square analysis. The staining was performed on 141 paraffin-embedded surgical specimens collected between 1991 and 1992 using a
monoclonal anti-NM23-H1 antibody. Follow-up of patients was until time of death or for 5 years. There was a very significant inverse
association between tumour staging and NM23-H1 status (P = 0.0004). However, NM23-H1 expression was not significantly correlated to
overall 5-year survival, disease recurrence, tumour differentiation, age or sex. Thus, although NM23-H1 may be involved in suppressing
metastasis, NM23-H1 immunohistochemistry has no prognostic value in colorectal cancer. This is the first report of a significant inverse
association of NM23-H1 status with tumour staging in colorectal cancer which showed no correlation with overall survival or disease
recurrence. Our result thus cautions against the practice of equating an inverse relation of genetic markers with tumour staging to survival or
disease recurrence.
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Tumour metastasis is the main cause of cancer mortality.
Metastasis is a multistep complex process involving the up- or
down-regulation of many different kinds of molecules, such as
surface receptors, proteases and their inhibitors, motility factors,
growth and organ specificity-determining factors from the
microenvironment and angiogenesis-promoting molecules (Ruiz
and Gunthert, 1996). Our understanding ofmetastasis is still at its
infancy. It is thus imperative that concerted efforts be made to
identify the factors involved and to ascertain their relative contri-
bution to metastasis. One clinical application of these molecules
would be their use as prognostic markers in cancer control.
The nm23 gene (non-metastatic clone no. 23) was identified by
differential colony hybridization performed on several murine K-
1735 melanoma cell sublines of varying metastatic potential.
nm23 RNA was tenfold greater in the low-metastatic-potential K-
1735 lines compared with the high-metastatic-potential K-1735
lines (Steeg et al, 1988). Transfection ofnm23 cDNA into murine
cell lines ofhigh metastatic potential resulted in the suppression of
metastatic potential using motility and colonization assays (Leone
et al, 1991a). This implies that nm23 is a potential metastasis-
suppressor gene and could function in the invasion and migration
steps ofthe metastatic pathway.
Thus far, two human nm23 genes, nm23-HJ and nm23-H2, have
been cloned (Stahl et al, 1991). They are 88% homologous to each
other and encode two polypeptide subunits ofa nucleoside diphos-
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phate (NDP) kinase. NDP kinase transfers the gamma phosphate
of nucleoside triphosphate to nucleoside diphosphate via a
high-energy phosphohistidine intermediate. It has been shown,
however, that the biological function ofNM23 is not related to its
NDP kinase activity (MacDonald et al, 1993). Rather, the motility-
suppressive function of NM23-HI is likely to be associated with
histidine-dependent phosphotransferase activity of the molecule
(Freije et al, 1997).
NM23 expression has been shown to be elevated in several
different tumours of lower metastatic potential than in the corre-
sponding tumours ofhigher metastatic potential, including breast,
hepatocellular, ovarian and gastric carcinomas and melanoma
(Rosa et al, 1995). In other tumours, such as neuroblastoma and
pancreatic carcinoma, surprisingly, the opposite trend has been
reported.
The role of NM23-H1 in colorectal carcinoma (CRC) is still
controversial. Conflicting observations have been reported at the
DNA, mRNA and protein level for the Western and Japanese
population. At the DNA level, allelic deletion or mutation of the
nm23-HJ gene appears to be associated with distant metastasis in
some studies (Cohn et al, 1991; Leone et al, 1991b; Wang et al,
1993; Cohn et al, 1997) but not others (Myeroff et al, 1993;
Whitelaw and Northover, 1994; Cawkwell et al, 1994). The
expression ofnm23-HJ mRNA has been found to be significantly
lower in more advanced tumours (Martinez et al, 1995) or
tumours associated with liver metastasis (Yamaguchi et al, 1993).
However, one study (Zeng et al, 1994) found that the mRNA
expression was associated with local CRC progression rather than
with metastasis. At the protein level, several studies have reported
an inverse association of NM23-H1 expression with tumour
staging (Yamaguchi et al, 1993; Martinez et al, 1995; Tannapfel et
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Figure 1 NM23-H1 immunostaining pattern in colorectal carcinomas. In all panels, the brown staining in the cytoplasm is NM23-H1 staining while the nuclei
are counterstained blue by haematoxylin. Tumour crypts that have strong intensity (A), moderate intensity (B), weakintensity (C) and no staining (D) are
illustrated (x 400 original magnification)
al, 1995), while others have found no significant association
(Royds et al, 1994; Lindmark, 1996). One recent study
(Indinnimeo et al, 1997) reported that overexpression of NM23-
HI in primary CRC could be linked to disease recurrence.
The purpose of this study was to evaluate whether the expres-
sion of the NM23-H1 protein by immunostaining is associated
with tumour stage, 5-year survival and disease recurrence in CRC
for the Singapore population, which is predominantly Chinese. In
addition, we also investigated the correlation ofNM23-H1 expres-
sion with grade oftumour differentiation, age and sex.
MATERIALS AND METHODS
Patient selection
A total of 141 archival specimens from patients (53 women and 88
men) who had undergone excision ofthe colon or rectum between
1991 and 1992 in the Singapore General Hospital were included in
the study. One pathologist routinely read all the specimens.
Tumour staging was according to Dukes' parameters (Dukes,
1932). Dukes' A/B are early tumours that are confined to the colon
and do not have metastatic secondaries, Dukes' C tumours have
lymph node metastasis and Dukes' D tumours have distant metas-
tasis. Patients whose radial resection margins are not cleared are
classified as Dukes' D (palliative) by the pathologist. Because of
the small number of Dukes' A patients (five), they were grouped
together with the Dukes' B patients. There were 51 Dukes' A/B,
59 Dukes' C and 31 Dukes' D patients. In this study, the mean
ages were 64, 61 and 64 years for Dukes' A/B, C and D respec-
tively. Twenty-two patients were aged 50 years and below, 26
patients were between 51 and 60 years, 54 patients were 61-70
years and 39 patients were more than 71 years old at time ofoper-
ation. Of the tumours studied, 107 were classified as moderately
differentiated, 14 were classified as poor and 11 as well differenti-
ated by one pathologist.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tumour tissues were cut into
4-jim-thick sections, deparaffinized in xylene and rehydrated. The
slides were incubated in microwaved 0.01 M citrate buffer, pH 6.0,
for 15 min for antigen retrieval. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide in water for 10min.
Sections were preincubated with 10% normal goat serum to reduce
non-specific staining. The slides were incubated with a 1:30dilution
ofaprimary monoclonal antibody (NM23 Ab-1, cloneNM301 from
Oncogene Science) at room temperature for 2 h, washed with
phosphate-buffered saline (PBS) and followed with a biotinylated
secondary goat anti-mouse antibody (Dako no. E433) for 30 min.
The slides were washed and incubated with strepavidin-
biotin-peroxidase complex (Dako no. K377) for another 30 min.
Diaminobenzidine (DAB) was used as a chromogen for colour
development. Omission oftheprimary antibody was carried out as a
negative control. The slides were counterstained with haematoxylin,
mounted and scored using a Zeiss Axioskop microscope.
Scoring
The slides were scored independently by two individuals (CPY
and CX) based on the criteria of intensity and proportion of
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Table 1 Correlation between NM23-H1 immunostaining in CRC and clinicopathological parameters




Female 53 (37.6) 32 21
Male 88 (62.4) 54 34 0.013 0.91
Age (years)
< 51 22 (15.6) 13 9
51-60 26 (18.4) 13 13
61-70 54 (38.3) 37 17
> 71 39 (27.7) 23 16 2.71 0.44
Dukes' stage
A/B 51 (36.2) 20 31
C 59 (41.8) 43 16
D 31 (22.0) 23 8 15.94 0.0004
Survival
Death by CRC 53 (52.0) 34 19
Still alive 49 (48.0) 26 23 1.29 0.26
Disease recurrence
No 39 (84.8) 16 23
Yes 7 (15.2) 2 5 0.69a
Tumour differentiation
Well 11(8.3) 6 5
Moderate 107 (81.1) 65 42
Poor 14 (10.6) 10 4 0.83 0.52
aFisher's test.
staining. An agreed score based on the summation ofboth intensity
and proportion was given. A score of 0 was for no staining; 1 for
weak, 2 for moderate and 3 for intense staining. Figure 1 illustrates
the intensity of staining ofthe crypts. In Figure IA, the NM23-Hl
staining (brown) in the cytoplasm surrounding the haematoxylin-
stained (blue) nuclei was considered to be strong. In Figure lB, the
NM23-Hl staining in the crypts was moderate. In Figure IC, the
NM23-H1 staining was weak and only slightly above background.
Figure ID shows two crypts from a slide that had no NM23-HI
staining. The tumour crypts, however, were heterogenously stained
and crypts of varying intensity occur on the same slide. Thus, the
score forintensity was based on the average intensity ofthe NM23-
HI staining on the whole slide. The score for the proportion ofcells
stained ranged from 0 for no cell stained, 1 for less than one-third of
the cells stained, 2 forbetween one-third and two-thirds ofthe cells
stained and 3 for more than two-third ofthe cells stained. The score
for intensity was added to the score for proportion stained to get a
composite score, ranging from 0 to 6. A score of 0 meant no
staining; a score of 1 or 2 was weak, a score of3 or 4 was moderate
and a score of5 or 6 was strong staining.
Statistical analysis
Contingency tables and chi-squared test (Pearson) were used to
evaluate the relationship, if any, between NM23-H1 expression
and tumour staging, 5-year survival, grade of tumour differentia-
tion, sex and age. Fisher's exact test was used to assess the rela-
tionship ofNM23-H1 staining and disease recurrence. Differences
were taken as significant when P (two-tailed) was less than 0.05.
RESULTS
NM23-H1 staining pattern
In the normal mucosa, NM23-H1 protein was expressed in the
cytoplasm ofthe interstitial epithelial cells of the crypts but not in
the goblet cells. Expression was also found in the cytoplasm ofthe
stromal cells. The cytoplasmic staining was consistent with its
deduced role as a cytokine response element to effect its biological
function (MacDonald et al, 1993). In the tumour crypts, the
staining remained in the cytoplasm and varied from strong to no
staining compared with the cytoplasm ofthe neighbouring stromal
cells (Figure 1). Twenty-four samples had no staining, 62 had
weak staining, 44 had moderate and 11 had strong staining. The
no- or weak-staining slides were grouped together as weak and the
moderate- and strong-staining slides were grouped together as
strong for statistical analysis.
NM23-H1 expression stratified by Dukes' staging
Table 1 shows that the NM23-H1 expression pattern had a signifi-
cant inverse correlation (P = 0.0004) with tumour staging. Of the
early cancer patients (Dukes' A/B), 60.8% had strong NM23-H1
staining, while only 27.1% ofthe intermediate stage (Dukes' C) and
25.8% of the late stage (Dukes' D) patients had strong NM23-H1
expression. Conversely, 39.2% ofthe Dukes A/B patients had weak
NM23-H1 staining, while 72.9% of the Dukes' C and 74.2% ofthe
Dukes' Dpatients hadweakNM23-HI immunoreactivity (Figure2).
The results indicate that the expression of NM23-H1 in early-stage









Figure 2 Percentages of strong (S) and weak (W) NM23-H1 immunostainings in Dukes' A/B, C and D stages
cancer is more likely to be elevated than in the later stages, when
there is lymph node metastasis and/ordistant metastasis.
NM23-H1 expression stratified by 5-year survival
NM23-H1 immunoreactivity was not significantly correlated with
the 5-year survival ofthe patients studied (Table 1, P = 0.26). This
implies that, although the NM23-H1 expression was inversely
correlated to tumour staging, it apparently had no predictive value
for the overall survival of the patients. The correlation of NM23-
H1 expression with death by colorectal cancer adjusted for tumour
staging was also not significant (P = 0.37). Survival data were
available for 102 patients only.
NM23-H1 expression in Dukes' A/B stage stratified by
local recurrence/distant metastasis
-
NM23-H1 expression in early-stage tumour (Dukes' A/B) was not
significantly correlated with disease recurrence or distant metas-
tasis over the 5-year period studied (Table 1, P = 0.69). This
implies that there is no statistically significant difference in the
probability ofa Dukes' A/B patient with strong NM23-H1 staining
and a Dukes' A/B patient with weak NM23-H1 staining to have a
local recurrence or distant metastasis. Thus, NM23-H1 expression
is not a good predictor for local recurrence or distant metastasis in
early-stage CRC. Disease recurrence data were available for 46
Dukes' A/B patients.
NM23-H1 expression stratified by tumour
differentiation, age and sex
There was no significant correlation between NM23-HI expres-
gion and grade oftumour differentiation (Table 1, P = 0.52). There
is thus no difference in NM23-H1 staining pattern between poor-,
moderate- or well-differentiated tumour. There was also no signif-
icant correlation between NM23-HI expression and age (Table 1,
P = 0.44) and NM23-Hl expression and sex (Table 1, P = 0.91).
This shows that there was no difference in the NM23-H1 expres-
sion between male and female patients nor between patients of
various age groups.
DISCUSSION
This is one of the biggest series studying the NM23-H1 protein,
showing NM23-Hl expression to be inversely correlated to
tumour staging. This implies that, for the Singapore cohort,
NM23-Hl expression in the early stage, i.e. lower-metastatic-
potential CRC, is elevated compared with the late-stage CRC of
higher metastatic potential. Our result thus supports the initial
observations made in melanoma and in breast carcinomas (Rosa et
al, 1995) and thatofMartinez et al (1995) inCRC, who showedby
immunoblotting that significantly more early-stage tumour tissues
have elevated NM23-H1 expression (compared with the adjacent
mucosa) than later-stage tumour tissues.
Nevertheless, in our patients, there was no significant correla-
tion between NM23-H1 expression and the overall 5-year survival
rate. One study reported a marginal significance in the inverse
association of death from colorectal cancer and NM23 status
(Royds et al, 1994). The authors studied 46 patients and used a
polyclonal antibody that could cross-react with NM23-H2. The
number of cases studied was therefore small, and it is uncertain
whatproportion ofthe results can be attributed toNM23-H1 alone.
The same study, however, did not find any association between
NM23 status and tumour staging. One 5-year follow-up study
reported that NM23-H1 immunoreactivity was not related to
metastasis-free survival and overall survival for 40 primary CRC
British Journal ofCancer(1998) 77(7), 1164-1168
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patients (Cohn et al, 1997). Another study found no significant
correlation between NM23-H1 staining with overall survival for
202 CRC patients followed over a9-yearperiod (Lindmark, 1996).
The findings from these two studies were thus similar to ours.
However, we showed that NM23-H1 staining patterns were
inversely correlated to tumour stages that were not documented by
these studies.
One recent study reported that NM23-H1 protein expression
was elevated in 12 out of20 primary CRC, and in four ofthese the
disease recurred (Indinnimeo etal, 1997). The authors inferred that
a strong NM23-H1 protein expression was correlated with disease
recurrence. In contrast, our data from 46 early-stage (Dukes' A/B)
patients indicate that for the local population, NM23-H1 expres-
sion in early-stage CRC patients was not significantly correlated
with local recurrence or distant metastasis.
We were unable to find any significant relation between tumour
differentiation and NM23-H1 staining pattern. However, more
than 80% of our samples were moderately differentiated, thus
statistical analysis may not have been meaningful.
It is not surprising that no correlation between NM23-H1
expression and age or sex was found, as most NM23-H1 studies in
CRC that had included age or sex found no association between
these variables and NM23-H1 staining pattern (Yamaguchi et al,
1993; Royds et al, 1994; Zeng et al, 1994; Lindmark et al, 1996).
In conclusion, our results indicate that, although NM23-H1
protein expression is inversely correlated with tumour staging by
Dukes' criteria, its expression is not sufficient to predict the 5-year
survival rate ofCRC patients nor is it sufficient to predict whether
an early-stage CRC would progress to more invasive tumour. Thus
far, the CRC studies that have reported an inverse relation between
NM23-H1 protein expression and tumour staging (Yamaguchi et
al, 1993; Martinez et al, 1995; Tannapfel et al, 1995) had no data
on overall survival or disease recurrence. Hence, we believe our
result is the first reported instance whereby a significant inverse
relation between NM23-H1 immunostaining status and tumour
staging is not followed by a significant relation with overall
survival or disease recurrence in CRC. Our result cautions against
the practice oftaking a significant inverse correlation with tumour
staging as being equivalent to having a predictive value on
survival or disease recurrence. A positive correlation does not
necessarily imply a causal relationship and, although NM23-H1
may be involved in suppressing metastasis as indicated by its
elevated expression in tumours of lower metastatic potential, it is
apparently not a major factor in metastasis suppression and hence
is not an independent prognostic indicator in CRC. NM23-H1
could be one ofthe factors involved in suppressing early stages of
metastasis, such as invasion and migration, as it has been shown to
suppress motility and colonization in melanoma and breast carci-
noma cell lines (Leone et al, 1991a; Freije et al, 1997). However,
its role in CRC could presumably be replaced by other cellular
proteins whose activity could be up-regulated with a concomitant
down-regulation of the NM23-HI level in late-stage tumours
through some yet unidentified interactive pathway. In addition,
NM23-H1 expression has no significant correlation with the grade
of tumour differentiation, age or sex.
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